



THOMSON REUTERS

**BioCentury**<sup>®</sup>

## ***Future Leaders in the Biotech Industry*** **Attracts Standing Room Only Audience**

### **BioCentury and Thomson Reuters Set to Host 17th Annual *NewsMakers in the Biotech Industry* Conference September 15, 2010 in New York City**

**April 14, 2010** -- In the midst of the current bull market for biotech stocks, a record number of investors, pharmaceutical business development professionals and biotech CEOs converged at the 17th Annual *Future Leaders in the Biotech Industry* conference in New York City on April 8. *Future Leaders* sets the table for the ***NewsMakers in the Biotech Industry*** conference in New York City on September 15, where BioCentury and Thomson Reuters will showcase public biotech companies with key upcoming milestones that will drive the biotech sector into 2011.

The prospect for fresh investment opportunities attracted money managers who control \$1.2 trillion in equity assets, \$140 billion in healthcare assets, and \$33 billion in biotech assets to *Future Leaders*.

The 42 members of the *Future Leaders* Class of 2010 -- the largest in the history of this conference -- were independently selected by BioCentury Publications, Inc. and Thomson Reuters. The members were selected for their potential to deliver upside for investors and pharma deal makers on the basis of differentiated products, upcoming news flow, ability to attract capital and the availability of partner-ready assets.

The 24 public companies at *Future Leaders* collectively had gained 100% over the past year, easily out-distancing the 37% jump in the BioCentury 100 Index and the 38% gain in the NASDAQ Biotechnology Index (NBI). Over that same period, the aggregate market cap of the *Future Leaders* public companies had more than doubled to \$7 billion.

The disease space covered by the presenting companies included cancer, infectious diseases, neurology, gastrointestinal, cardiovascular and metabolic disorders. [CLICK HERE](#) for more information on the Presenting Companies.

"In tandem with market momentum, BioCentury and Thomson Reuters look forward to the return of the investment community in an equally large turnout for *NewsMakers*," said BioCentury President & CEO David Flores. "Both the Street and pharma deal makers know that *NewsMakers*, now in its 17th year, is the venue that launches the fall investment season."

Thomson Reuters and BioCentury acknowledge *Future Leaders* Gold Sponsor Cooley Godward Kronish LLP for its continuing support of the conference and the prestigious *Future Leaders* sponsors from both the public and private capital markets: OrbiMed Advisors, Rodman & Renshaw, WBB Securities, Wedbush Pacific Growth Life Sciences and Yorkville Advisors.

-more-



THOMSON REUTERS

**BioCentury**<sup>®</sup>

## The 2010 *Future Leaders* Presenting Companies

Presenting companies were screened using Thomson Reuters and BioCentury industry analysis and proprietary databases, including BioCentury's *BCIQ* online business intelligence platform. The result provided an independently selected mix of companies with proven fundraising capacity, the prospect for key partnerships and proximity to potentially transformational milestones. (Stock symbols shown for publicly traded companies; listed on NASDAQ unless noted).

**Akebia Therapeutics Inc.**  
**Allos Therapeutics Inc.** (ALTH)  
**Amarin Corp. plc** (AMRN)  
**ArQule Inc.** (ARQL)  
**Biota Holdings Ltd.** (ASX:BTA)  
**Calistoga Pharmaceuticals Inc.**  
**Chelsea Therapeutics International Ltd.** (CHTP)  
**ChemoCentryx Inc.**  
**Chimerix Inc.**  
**Clinical Data Inc.** (CLDA)  
**Curis Inc.** (CRIS)  
**Cytori Therapeutics Inc.** (CYTX; Xetra:XMPA)  
**Depomed Inc.** (DEPO)  
**Dyax Corp.** (DYAX)  
**Enobia Pharma Inc.**  
**Exact Sciences Corp.** (EXAS)  
**Five Prime Therapeutics Inc.**  
**Gemin X Pharmaceuticals Inc.**  
**Globelmmune Inc.**  
**Inovio Biomedical Corp.** (NYSE-A:INO)  
**iPierian Inc.**

**KAI Pharmaceuticals Inc.**  
**KaloBios Pharmaceuticals Inc.**  
**Lux Biosciences Inc.**  
**Micromet Inc.** (MITI)  
**Neoprobe Corp.** (OTCBB:NEOP)  
**NeurogesX Inc.** (NGSX)  
**Newron Pharmaceuticals S.p.A.** (SIX:NWRN)  
**PDL BioPharma Inc.** (PDLI)  
**Pharming Group N.V.** (Euronext:PHARM)  
**Plexxikon Inc.**  
**Protalix Biotherapeutics Inc.** (PLX)  
**PTC Therapeutics Inc.**  
**Regulus Therapeutics Inc.**  
**Relypsa Inc.**  
**RXi Pharmaceuticals Corp.** (RXII)  
**Seaside Therapeutics LLC**  
**Singulex Inc.**  
**SuperGen Inc.** (SUPG)  
**Trubion Inc.** (TRBN)  
**Vivus Inc.** (VVUS)  
**Willex AG** (Xetra:WL6)

### About BioCentury

BioCentury Publications, Inc. provides essential biopharma industry intelligence from five offices in the U.S. and Europe. For more than 17 years, a global audience of biotech and pharmaceutical executives and investors has benefited from BioCentury's deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company's publications, data products and collaborative industry conferences in the U.S., Europe and Asia. BioCentury's titles include the flagship *BioCentury*, the *Bernstein Report on BioBusiness*; its *SciBX: Science-Business eXchange* translational science joint publishing venture with Nature Publishing Group; and its *BioCentury Extra* online daily newspaper. These timely journals are backed by *BCIQ: BioCentury Online Intelligence*, an online business intelligence resource. For more information, visit [www.biocentury.com](http://www.biocentury.com).

### About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to



THOMSON REUTERS

**BioCentury**<sup>®</sup>

leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people and operates in over 100 countries. For more information, go to [www.thomsonreuters.com](http://www.thomsonreuters.com).

###

BioCentury®, The Bernstein Report on BioBusiness™ and BCIQ are trademarks of BioCentury Publications, Inc. SciBX and SciBX: Science-Business eXchange are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.

## CONTACT

Jeanette Volpi  
Thomson Reuters  
PR Director, Investment & Advisory  
+ 1 646 223 5517  
[jeanette.volpi@thomsonreuters.com](mailto:jeanette.volpi@thomsonreuters.com)

Thomas C. Carey  
Vice President of Commercial Operations  
BioCentury Publications, Inc.  
+1 650 595-5333/[tcarey@biocentury.com](mailto:tcarey@biocentury.com)